A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group

D. Peest, H. Deicher, R. Coldewey, R. Leo, R. Bartl, H. Bartels, H. J. Braun, W. Fett, J. T. Fischer, B. Göbel, P. Harms, R. Henke, L. Hoffmann, E. D. Kreuser, W. D. Maier, C. R. Meier, J. Oertel, M. Petit, M. Planker, C. PlatzeckM. Respondek, E. Schäfer, K. Schumacher, M. Stennes, W. Stenzinger, C. Tirier, H. Wagner, H. J. Weh, P. von Wussow, J. Wysk

Research output: Contribution to journalArticlepeer-review

62 Scopus citations

Abstract

406 untreated multiple myeloma patients of stage I (n = 54), U (n = 148) and III (n = 204) were enrolled in the trial. 51 54 stage I and 60 148 stage II patients were asymptomatic and followed without treatment until disease progression (progression free survival: 60% after 4 years for stage I versus 50% after 1 year for stage II). Symptomatic patients of stage I (n = 3 54) and II (n = 88 148) presenting with tumour progression, received melphalan 15 mg/m2 intravenously (i.v.) and prednisone 60 mg/m2 oral days 1-4 (MP). Stage II disease remission rate was 59%, and 50% tumour related survival (TRS) was 59 months. Stage III patients were randomised to receive MP or VBAMDex (vincristine/BCNU/doxorubicin/melphalan/dexamethasone) treatment. 43% of MP treated patients responded compared with 64% of the VBAMDex group. 50% TRS was 36 months in both groups without a detectable difference. 117 responders of stage II and III with stable disease were randomised to receive either IFN-α (5 × 106IU, subcutaneous (S.C.) 3 times per week) or no maintenance treatment. The relapse rate in both groups was 50% after 13 months. No survival benefit for IFNα treated patients was observed (50% TRS: 45 months).

Original languageEnglish (US)
Pages (from-to)146-151
Number of pages6
JournalEuropean Journal of Cancer
Volume31
Issue number2
DOIs
StatePublished - 1995
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group'. Together they form a unique fingerprint.

Cite this